[225] Actinium-PSMA radioligand therapy for metastatic castration-resistant prostate cancer

This retrospective, international study examined the safety and antitumor activity in 488 patients who had received previous treatment including docetaxel, cabazitaxel, abiraterone, and enzalutamide, lutetium-177 PSMA, and radium-223 dichloride.

A decline in PSA was noted in 73% of patients, with 33% achieving a response on PET. Patients with at least a 50% decline in PSA had better survival outcomes. The median overall survival was 15.5 months and the median progression-free survival was 7.9 months.

Extremely dry mouth (xerostomia) was a common side effect. Severe bone marrow and renal toxicity were less common adverse events. No serious adverse events or treatment- related deaths were recorded.

[225]AC-PSMA RLT demonstrated a substantial antitumor effect in mCRPC and is a viable option in patients previously treated with approved methods.

Oncology. February 1, 2024.